Literature DB >> 7527591

Overview of platinum chemotherapy in head and neck cancer.

A A Forastiere1.   

Abstract

Platinum-based chemotherapy has been used to treat head and neck cancer for approximately 15 years. For patients with recurrent disease, cisplatin/5-fluorouracil (5-FU) and carboplatin/5-FU combinations have proved superior to single agents in producing higher overall response rates. However, survival rates are not substantially affected, indicating a need to identify alternative new agents with activity. Newly diagnosed patients with advanced stages III and IV disease generally have a poor prognosis. The most common site of failure and cause of death is locoregional recurrence. To improve survival and alter patterns of failure in this population, platinum-based chemotherapy regimens have been combined with surgery or radiotherapy as initial curative treatment. Cisplatin/5-FU chemotherapy in this setting is effective in significantly reducing the incidence of distant metastases as shown in several randomized trials. The sole indication for induction chemotherapy in patients with advanced laryngeal cancer is as an alternative to laryngectomy. The Department of Veterans Affairs Laryngeal Cancer Study Group trial demonstrated no significant differences in survival in patients who received induction cisplatin/5-FU and radiotherapy or total laryngectomy and postoperative radiotherapy. An alternative approach utilizing cisplatin or carboplatin alone or combined with 5-FU, administered simultaneously with radiotherapy, is under investigation. Pilot data suggest that this approach may be more effective in improving locoregional control and hence survival. Three intergroup prospective, randomized trials currently are comparing sequential chemoradiotherapy, simultaneous chemoradiotherapy, and standard radiotherapy alone in advanced nasopharyngeal cancer, advanced resectable laryngeal cancer, and unresectable cancers from other sites in the head and neck. These trials are designed to definitively address questions of treatment modality sequence and its impact on pattern of failure and survival.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527591

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  11 in total

1.  Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity.

Authors:  Anbarasi Kothandapani; Kathirvel Gopalakrishnan; Bhaskar Kahali; David Reisman; Steve M Patrick
Journal:  Exp Cell Res       Date:  2012-06-18       Impact factor: 3.905

Review 2.  Clinical pharmacokinetics and dose optimisation of carboplatin.

Authors:  S B Duffull; B A Robinson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

3.  Regression of Dalton's lymphoma in vivo via decline in lactate dehydrogenase and induction of apoptosis by a ruthenium(II)-complex containing 4-carboxy N-ethylbenzamide as ligand.

Authors:  Raj K Koiri; Surendra K Trigun; Lallan Mishra; Kiran Pandey; Deobrat Dixit; Santosh K Dubey
Journal:  Invest New Drugs       Date:  2008-11-29       Impact factor: 3.850

Review 4.  Therapeutic Intensification and Induction Chemotherapy for High-Risk Locally Advanced Squamous Cell Carcinoma.

Authors:  Maria Grazia Ghi; Adriano Paccagnella
Journal:  Curr Treat Options Oncol       Date:  2019-01-11

5.  2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells.

Authors:  Andrean L Simons; Iman M Ahmad; David M Mattson; Kenneth J Dornfeld; Douglas R Spitz
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

6.  Carboplatin and tegafur-uracil concomitant with standard radiotherapy in the management of locally advanced head and neck cancer.

Authors:  Angel Segura Huerta; Roberto Díaz-Beveridge; José A Pérez-Fidalgo; Verónica Calderero Aragón; Miguel Pastor Borgoñón; Jorge Aparicio Urtasun; Joaquín Montalar Salcedo
Journal:  Clin Transl Oncol       Date:  2005 Jan-Feb       Impact factor: 3.405

Review 7.  Glucose deprivation-induced metabolic oxidative stress and cancer therapy.

Authors:  Andrean L Simons; David M Mattson; Ken Dornfeld; Douglas R Spitz
Journal:  J Cancer Res Ther       Date:  2009-09       Impact factor: 1.805

8.  Cisplatin combined with zidovudine enhances cytotoxicity and oxidative stress in human head and neck cancer cells via a thiol-dependent mechanism.

Authors:  David M Mattson; Iman M Ahmad; Disha Dayal; Arlene D Parsons; Nukhet Aykin-Burns; Ling Li; Kevin P Orcutt; Douglas R Spitz; Kenneth J Dornfeld; Andrean L Simons
Journal:  Free Radic Biol Med       Date:  2008-10-18       Impact factor: 7.376

Review 9.  Nuclear medicine imaging for the assessment of primary and recurrent head and neck carcinoma using routinely available tracers.

Authors:  Hubert Vermeersch; David Loose; Hamphrey Ham; Andreas Otte; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-22       Impact factor: 9.236

10.  Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging.

Authors:  Andrean L Simons; Melissa A Fath; David M Mattson; Brian J Smith; Susan A Walsh; Michael M Graham; Richard D Hichwa; John M Buatti; Ken Dornfeld; Douglas R Spitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-15       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.